Patient P-01619

Synthetic patientNBL-101 · Day 119 · 35–44 · M · baseline S14Steering view · 3D Open companion preview

Therapy response

Unstable

Tolerance

Unstable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

93%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 47 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 52 SC-12 recommended — Supportive Compound SC-12
Day 53 Patient declined — Not now
Day 56 GI-04 recommended — GI Support Protocol GI-04
Day 57 Patient accepted — Started GI-04 in the companion
Day 65 No meaningful change — GI Support Protocol GI-04

What changed?

Trajectory began diverging from predicted response on Day 47.

Primary contributors, last 14 days

Inflammatory activity+5
Toxicity+5
GI instability+4
Treatment adherence+4
Nutritional resilience-2

What helped?

Supportive Compound SC-12Day 52
Declined by patient
GI Support Protocol GI-04Day 56
Result: no meaningful change

LIFE OS recommendation

Dietary Support Protocol NP-02

59%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

76.1/100

stable · +0.8 vs previous 14 d

Toxicity

Blood

62/100

improving · -2.4 vs previous 14 d

Sleep quality

Wearable

24.9/100

worsening · -2.3 vs previous 14 d

Energy level

Daily log

0.7/10

stable · -0.0 vs previous 14 d

Stress level

Daily log

7.2/10

stable · -0.3 vs previous 14 d

Steps

Wearable

5,336

improving · +460 vs previous 14 d

Adherence

Companion

41.7 %

stable · +1.1 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 17 from the failing basin, 86 from restoration.

Would help

ME-01 Monitoring Escalation
100% improved among 77 similar · onset 3 d · confidence 71%
NP-02 Dietary Support Protocol
63% improved among 64 similar · onset 10 d · confidence 71%
SC-12 Supportive Compound
76% improved among 51 similar · onset 6 d · confidence 71%

Would not help

GI-04 GI Support Protocol
already tried, no meaningful change
Keep fat low
GI +6.2 next day on high-intake days · n 25
Keep histamine low
GI +5 next day on high-intake days · n 18
Keep alcohol low
GI +4.9 next day on high-intake days · n 22

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+6.2detractor · 95%
Histamine load
+5detractor · 95%
Alcohol
+4.9detractor · 95%
Insoluble fibre
+3.8detractor · 95%
Simple carbohydrates
+3.2detractor · 82%
Spicy / capsaicin
-1.3no signal · 28%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 76 and rising
- WearableSleep 6.1 h, below personal baseline
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 26/100
- Daily logFibre intake low in recent food logs
Drug metabolism and exposure ↑55
- DNADPYD *2A → slower clearance
- BloodToxicity index 62
Autonomic recovery ↓45
- WearableResting HR 79 bpm
- WearableShort sleep window
Inflammatory signalling ↑40
- BloodInflammatory load index 71
- WearableHRV 32 ms, trending down

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
DPYD *2A heterozygous
Slower drug clearance
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 1.9 · butyrate capacity 26/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 34 ms
Sleep: 5.8 h
Steps: 4,879
Resting HR: 78 bpm

Daily log: GI score 76, nutritional resilience 31, adherence 42.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01582	57%	S14	GI-04	no change	45
P-01866	56%	S14	—	—	40
P-01407	52%	S14	NP-02	no change	44
P-01605	52%	S14	ME-01	improved	41
P-01615	52%	S14	ME-01	improved	48
P-01728	51%	S14	SC-12	improved	41
P-01762	50%	S14	NP-02	no change	40
P-01572	49%	S14	GI-04	worsened	41
P-01720	49%	S14	NP-02	improved	47
P-01721	49%	S14	—	—	37
P-01772	49%	S20	NP-02	no change	50
P-01830	49%	S14	—	—	44